Lung Cancer |

Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation: Response to Chemotherapy FREE TO VIEW

Uthara Vijai Kumar
Author and Funding Information

Yashoda Hospitals, Hyderabad, India

Chest. 2014;146(4_MeetingAbstracts):591A. doi:10.1378/chest.1994567
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Posters I

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: To study the clinical profile of patients in a private hospital setting diagnosed with Non small cell lung cancer (NSCLC) with Epidermal growth factor receptor (EGFR) mutation positivity To assess Median Progression free survival (PFS), Overall survival (OS) and Objective Response Rate (ORR)

METHODS: Study design : Non comparative Cohort study Study setting: Pulmonology OPD of Yashoda Hospitals, Secunderabad Study duration: 26 months Sample size: 30 All patients above 18 years of age who were diagnosed with NSCLC with EGFR mutation positivity recieved oral tyrosine kinase inhibitor therapy as first line chemotherapy Dose: 250 mg once daily

RESULTS: Median PFS [95%CI](months) 13.24 Overall survival [95%CI](months) 26.22 Stable disease : 33% complete response: 7% partial response :30% progressive disaese: 30%

CONCLUSIONS: 1. Every diagnosis of adenocarcinoma lung should be followed by testing for exon 19 deletion 2. advisable to keep 2-3 unstained slides of tissue material to test for EGFR mutation 3. Oral chemothepeutic agents such as tyrosine kinase inhibitors (Gefitinib and Erlotinib) have shown excellent patient compliance , lesser side effects and good progression free survival rates 4. Most patients were Women between 45-65 yrs of age and never smokers

CLINICAL IMPLICATIONS: 1. Any unresolved cough or pneumonia on Chest X ray , think Lung cancer 2. In women , never smokers , age 45- 65 yrs with a non resoving pneumonia , think NSCLC 3. EGFR mutation to be tested for every diagnosis of NSCLC 4. Cost effective , Easy to administer oral tyrosine kinase inhibitors can be offered to such patients as first line chemotherapy

DISCLOSURE: The following authors have nothing to disclose: Uthara Vijai Kumar

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543